Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment | Zendy

Firouzé BaniSadr | Zendy; Fabrice Carrat | Zendy; Éric Rosenthal | Zendy; Lionel Piroth | Zendy; Patrice Morand | Zendy; Françoise LunelFabiani | Zendy; M. Bonarek | Zendy; Nathalie Verdière | Zendy; Gilles Pialoux | Zendy; P. Cacoub | Zendy; Stanislas Pol | Zendy; Christian Perronne | Zendy

Open Access

Spontaneous Hepatic Decompensation in Patients Coinfected with HIV and Hepatitis C Virus during Interferon-Ribavirin Combination Treatment

Author(s) -

Firouzé BaniSadr,

Fabrice Carrat,

Éric Rosenthal,

Lionel Piroth,

Patrice Morand,

Françoise LunelFabiani,

M. Bonarek,

Nathalie Verdière,

Gilles Pialoux,

P. Cacoub,

Stanislas Pol,

Christian Perronne

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/498312

Subject(s) - ribavirin , medicine , decompensation , virology , hepatitis c virus , interferon , hepatitis c , human immunodeficiency virus (hiv) , virus , immunology , gastroenterology

Spontaneous hepatic decompensation was observed in 7 of 383 patients coinfected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) who were receiving treatment with interferon and ribavirin. Multivariate analysis identified the following risk factors: didanosine use (odds ratio [OR], 8.8; 95% confidence interval [CI], 1.2-102.3; P < .02), cirrhosis, (OR, 8.8; 95% CI, 1.2-104.2; P<.02), and elevated total bilirubin level (OR, 7.9; 95% CI, 1.08-93.3; P<.03). Didanosine should thus not be given to patients with cirrhosis, particularly when treatments for HCV and HIV infections have to be administered concomitantly.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research